levonorgestrel

Small moleculeexperimental

Levonorgestrel is a hormonal medication used in a number of birth control methods. It is combined with an estrogen to make combination birth control pills. As an emergency birth control, sold under the brand names Plan B One-Step and Julie, among others, it is useful within 72 hours of unprotected sex. The more time that has passed since sex, the less effective the medication becomes. Levonorgestrel works by preventing or delaying ovulation so an egg cannot be released. The dosage used for emergency contraception is ineffective when ovulation has already occurred, and has been found to have no effect on implantation. It decreases the chances of pregnancy by 57–93%. In an intrauterine device (IUD), such as Mirena among others, it is effective for the long-term prevention of pregnancy. A levonorgestrel-releasing implant is also available in some countries. — Wikipedia

Clinical trial activity

86 trials · 89 clinical orgs · 0 marketing orgs

Phase 1
48
Phase 2
21
Phase 3
11
Phase 4
9

Earliest trial started Apr 1, 2012 (NCT01601366)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • levocept

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07222228Phase 2Apr 1, 2026National Institutes of Health (NIH), Premier Research Group
NCT07190430Phase 1Oct 3, 2025Pfizer
NCT07074327Phase 1Jul 11, 2025Vertex
NCT07010146Phase 2Jul 1, 2025National Institutes of Health (NIH), University of Virginia
NCT06942936Phase 1May 28, 2025AstraZeneca, Parexel
NCT06799884Phase 1Jan 18, 2025Idorsia Pharmaceuticals Ltd.
NCT06727734Phase 3Dec 31, 2024The Family Planning Association of Hong Kong, The University of Hong Kong
NCT06620939N/ADec 1, 2024Jiao Tong University, Nanjing Medical University
NCT06657105Phase 1Nov 1, 2024AstraZeneca
NCT06492889Phase 2/Phase 3 (Phase 3)Jul 22, 2024Cuidado Integral de la Mujer, Gineclinic, S.C., Gynuity Health Projects
NCT06513104Phase 1Jul 18, 2024Novo Nordisk
NCT06455969Phase 4Jul 15, 2024United States Army, University of Pittsburgh
NCT06461039Phase 1Jun 14, 2024Novo Nordisk
NCT06380205Phase 1May 7, 2024Incyte
NCT06354257Phase 1Apr 5, 2024GlaxoSmithKline
NCT05903131Phase 2Jan 31, 2024National Cancer Institute (NCI), Washington University in St. Louis
NCT06188026Phase 1Dec 18, 2023Novo Nordisk
NCT05896384Phase 1Dec 7, 2023Boehringer Ingelheim
NCT06162611Phase 4Nov 6, 2023Planned Parenthood, University of Utah
NCT06071442Phase 1Oct 9, 2023Alexion
Showing 20 of 86 trials
Page 1 / 5

Organizations

Research & Development (89)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institutes of Health (NIH)Government9032017
PfizerFor profit8812018
Novo NordiskFor profit4412021
AstraZenecaFor profit3312022
BayerFor profit3322017
Boehringer IngelheimFor profit3312018
CONRADFor profit3232017
GrunenthalFor profit3312019
Health DecisionsFor profit3332018
Johnson and JohnsonFor profit3312017
National Institute of Allergy and Infectious Diseases (NIAID)Government3032018
University of UtahAcademic/Hospital3222016
University of WashingtonAcademic/Hospital3122018
Assiut UniversityAcademic/Hospital2222012
Cuidado Integral de la Mujer, Gineclinic, S.C.Academic/Hospital2022021
Gynuity Health ProjectsAcademic/Hospital2222021
Idorsia Pharmaceuticals Ltd.For profit2212020
International Partnership for Microbicides, Inc.Academic/Hospital2222018
Kenya Medical Research InstituteAcademic/Hospital2022018
National Cancer Institute (NCI)Government2022022
89 organizations
Page 1 / 5